Lupus Nephritis Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approval, NDA Approval, Mechanism of Action, Route of Administration, and Companies by DelveInsight

(Albany, United States) "Lupus Nephritis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lupus Nephritis Market.

As per DelveInsight's assessment, globally, Lupus Nephritis pipeline constitutes 35+ key companies continuously working towards developing 40+ Lupus Nephritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Lupus Nephritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample report @ https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Lupus Nephritis Pipeline Report:
• Lupus Nephritis Companies across the globe are diligently working toward developing novel Lupus Nephritis treatment therapies with a considerable amount of success over the years.
• Lupus Nephritis companies working in the treatment market are Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others, are developing therapies for the Lupus Nephritis treatment
• Emerging Lupus Nephritis therapies in the different phases of clinical trials are- IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others are expected to have a significant impact on the Lupus Nephritis market in the coming years.
• In February 2025, Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company focused on developing innovative small molecule therapies for immune-mediated diseases, announced its participation in a virtual Key Opinion Leader (KOL) event hosted by William Blair. The company will discuss the clinical development of zetomipzomib for autoimmune hepatitis (AIH) and share a safety update from the PALIZADE Phase 2b trial in patients with active lupus nephritis.
• In November 2024, Adicet Bio reported that the first patient with lupus nephritis (LN) has been administered ADI-001 in a Phase I clinical trial for autoimmune diseases.
• In November 2024, Kyverna Therapeutics announced plans to present updated clinical data on lupus nephritis (LN) patients treated with KYV-101 in the ongoing KYSA-1 and KYSA-3 Phase I/II studies, as well as named patient treatments.
• In October 2024, Kezar Life Sciences halted subject enrollment and patient dosing in the Phase II PALIZADE trial evaluating zetomipzomib for active lupus nephritis.
• In June 2024, Nkarta launched Ntrust-I, a multi-center clinical trial evaluating NKX019 for lupus nephritis, with the first patient undergoing screening. Additionally, the company received FDA clearance for its second Investigational New Drug (IND) application for NKX019 in autoimmune diseases.

Lupus Nephritis Overview
Lupus Nephritis is a serious kidney disorder caused by systemic lupus erythematosus (SLE), an autoimmune disease where the immune system mistakenly attacks healthy tissues. Lupus Nephritis leads to inflammation of the kidneys, impairing their ability to remove waste and excess fluids from the body. Lupus Nephritis commonly affects women of childbearing age and is more prevalent among certain ethnic groups, including African Americans, Hispanics, and Asians.

Lupus Nephritis symptoms can range from mild to severe and may include swelling in the legs and feet, high blood pressure, foamy urine, and weight gain due to fluid retention. Lupus Nephritis diagnosis typically involves urine tests, blood tests, kidney biopsy, and imaging studies to assess kidney function and detect abnormalities. Lupus Nephritis treatment focuses on controlling lupus activity and preserving kidney function using immunosuppressive drugs, corticosteroids, and biologic agents.

Lupus Nephritis prognosis depends on the severity and response to treatment, with early intervention improving long-term outcomes. Lupus Nephritis management requires regular monitoring and lifestyle adjustments to reduce flare-ups. Lupus Nephritis research is ongoing, with clinical trials exploring new therapies for improved efficacy and reduced side effects. Lupus Nephritis awareness and patient education are critical for early diagnosis and effective management of this chronic kidney condition.

Get a Free Sample PDF Report to know more about Lupus Nephritis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Lupus Nephritis Drugs Under Different Phases of Clinical Development Include:
• Secukinumab: Novartis
• Obinutuzumab: Roche
• GAZYVA: Roche
• Saphnelo (Anifrolumab): AstraZeneca
• Iscalimab: Novartis
• IBL-101: Inflection Biosciences
• RG 6107: Roche
• Itolizumab: Equillium
• Zanubrutinib: BeiGene
• Guselkumab: Janssen Research & Development
• Daxdilimab: Horizon Therapeutics
• Cosentyx: Novartis
• Ravulizumab: Alexion Pharmaceuticals
• Anifrolumab: AstraZeneca

Lupus Nephritis Route of Administration
Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Lupus Nephritis Molecule Type
Lupus Nephritis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Lupus Nephritis Pipeline Therapeutics Assessment
• Lupus Nephritis Assessment by Product Type
• Lupus Nephritis By Stage and Product Type
• Lupus Nephritis Assessment by Route of Administration
• Lupus Nephritis By Stage and Route of Administration
• Lupus Nephritis Assessment by Molecule Type
• Lupus Nephritis by Stage and Molecule Type

DelveInsight's Lupus Nephritis Report covers around 40+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Lupus Nephritis product details are provided in the report. Download the Lupus Nephritis pipeline report to learn more about the emerging Lupus Nephritis therapies
https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Lupus Nephritis Therapeutics Market include:
Key companies developing therapies for Lupus Nephritis are - Novartis, Novartis Pharmaceuticals, Hoffmann-La Roche, Janssen Research & Development, BeiGene, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Alexion Pharmaceuticals, Omeros Corporation, Corestem, Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Apellis Pharmaceuticals, AstraZeneca, Kezar Life Sciences, Equillium, Eledon Pharmaceuticals, Resolve Therapeutics, and others.

Lupus Nephritis Pipeline Analysis:
The Lupus Nephritis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Lupus Nephritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis Treatment.
• Lupus Nephritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Lupus Nephritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lupus Nephritis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Lupus Nephritis drugs and therapies
https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Lupus Nephritis Pipeline Market Drivers
• Increasing Prevalence of Lupus Nephritis, increase in research and developmental activities are some of the important factors that are fueling the Lupus Nephritis Market.

Lupus Nephritis Pipeline Market Barriers
• However, high-cost associated with the disease, lack of awareness among the patients about the disease and other factors are creating obstacles in the Lupus Nephritis Market growth.

Scope of Lupus Nephritis Pipeline Drug Insight
• Coverage: Global
• Key Lupus Nephritis Companies: Inflection Biosciences, Roche (SWX: ROG), Equillium (NASDAQ: EQ), BeiGene (NASDAQ: BGNE), BeiGene (SSE: 688235), Janssen Research & Development (subsidiary of Johnson & Johnson - NYSE: JNJ), Horizon Therapeutics (acquired by Amgen - NASDAQ: AMGN), Novartis (SWX: NOVN), AstraZeneca (NASDAQ: AZN), Alexion Pharmaceuticals (acquired by AstraZeneca - LSE: AZN), Equillium, and others.
• Key Lupus Nephritis Therapies: IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others
• Lupus Nephritis Therapeutic Assessment: Lupus Nephritis current marketed and Lupus Nephritis emerging therapies
• Lupus Nephritis Market Dynamics: Lupus Nephritis market drivers and Lupus Nephritis market barriers

Request for Sample PDF Report for Lupus Nephritis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Lupus Nephritis Report Introduction
2. Lupus Nephritis Executive Summary
3. Lupus Nephritis Overview
4. Lupus Nephritis- Analytical Perspective In-depth Commercial Assessment
5. Lupus Nephritis Pipeline Therapeutics
6. Lupus Nephritis Late Stage Products (Phase II/III)
7. Lupus Nephritis Mid Stage Products (Phase II)
8. Lupus Nephritis Early Stage Products (Phase I)
9. Lupus Nephritis Preclinical Stage Products
10. Lupus Nephritis Therapeutics Assessment
11. Lupus Nephritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Lupus Nephritis Key Companies
14. Lupus Nephritis Key Products
15. Lupus Nephritis Unmet Needs
16 . Lupus Nephritis Market Drivers and Barriers
17. Lupus Nephritis Future Perspectives and Conclusion
18. Lupus Nephritis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/chronic-pain-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Adamantinoma Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Dysthymia Market: https://www.delveinsight.com/report-store/persistent-depressive-disorder-market?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-syndrome-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.